Trials / Completed
CompletedNCT00720018
Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers
A Phase I, Single Center, Open Label, Single-Dose, Five-Period Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- NuPathe Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The primary objective is to compare the pharmacokinetics (PK) profiles among five NP101 patches in healthy volunteers. The secondary objective is to evaluate the safety of NP101 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NP101 Sumatriptan Iontophoretic Transdermal Patch | NP101 transdermal patch delivering sumatriptan for 4 hours. |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2008-07-22
- Last updated
- 2016-02-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00720018. Inclusion in this directory is not an endorsement.